Production (Stage)
Greenwich LifeSciences, Inc.
GLSI
$9.20
-$0.27-2.85%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -64.64% | 340.87% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -59.40% | 196.22% | |||
| Operating Income | 59.40% | -196.22% | |||
| Income Before Tax | 59.47% | -201.28% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 59.47% | -201.28% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 59.47% | -201.28% | |||
| EBIT | 59.40% | -196.22% | |||
| EBITDA | 59.41% | -196.30% | |||
| EPS Basic | 59.54% | -201.08% | |||
| Normalized Basic EPS | 59.55% | -201.18% | |||
| EPS Diluted | 59.54% | -201.08% | |||
| Normalized Diluted EPS | 59.55% | -201.18% | |||
| Average Basic Shares Outstanding | 0.18% | 0.04% | |||
| Average Diluted Shares Outstanding | 0.18% | 0.04% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||